TriangleCD30-Armed T Cells (NCT05544968)
CD30-Armed T Cells trial for Relapsed or Refractory Hodgkin Lymphoma and CD30+ Lymphomas (NCT05544968). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with Hodgkin lymphoma or other CD30 positive blood cancers that have come back or not responded to treatment.
The idea: collect the patient's own T cells, activate them, and coat them with a bispecific antibody that grabs CD30 on cancer cells and CD3 on the T cell. The armed T cells are then given back. This is the first time this treatment is tested in people.
The study looks at safety, feasibility, and how well it works.
This phase 1 study plans 42 patients. At the Medical College of Wisconsin in Milwaukee, Guru Subramanian Guru Murthy leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.